Actos Bladder Cancer Lawsuit Center
Diabetics who developed bladder cancer after taking a widely-used medication from Takeda Pharmaceuticals are urged to consider filing an Actos lawsuit. Despite its popularity in treating patients throughout the U.S. and abroad, recent research shows that patients prescribed this treatment may be at an increased risk for this disease, as well as heart problems and other serious health risks.
By filing an Actos bladder cancer lawsuit with Bernstein Liebhard LLP, you may be one step closer to receiving compensation for the lost wages, out-of-pocket medical expenses, as well as any pain and suffering you may have incurred as a result of your alleged injuries. Individuals who are not sure if they are eligible to file a claim against Takeda are urged to contact an Actos lawyer at the Firm today for a free and confidential case evaluation. Call us now at .
Over the past couple of years, the association between Actos and bladder cancer has continued to raise concern in the medical community. In June 2011, the U.S. Food & Drug Administration (FDA) mandated that new information regarding the drug’s association with bladder cancer be added to the “Warnings and Precautions” section of the Actos label. At the same time, the agency warned that patients who took Actos for a year or more could face an increased risk of developing the potentially fatal disease.
Since then, evidence of an Actos bladder cancer risk has only grown. For example, a study published in BMJ on March 31, 2012 revealed that diabetics taking the medication for two years may be at a doubled risk for bladder cancer than those who were not. Research released that July in CMAJ (the Canadian Medical Association) echoed these findings when its leaders found Actos users to be 22 percent more likely to develop the disease.
According to a report published that month by HealthDay News, background information on the analysis showed that people with type 2 diabetes have a 40 percent increased risk of developing bladder cancer due to high insulin levels.
Results of these studies have resulted in the filing of several individual and Actos class action lawsuits. These cases similarly allege Takeda’s failure to adequately warn patients about its product’s risk for side effects, which may include bladder cancer. Given these alleged side effects, plaintiffs go on to say that the medication was defectively designed.
Actos Bladder Cancer Lawsuit Filings Progress in Louisiana Federal Court
Court documents indicate that these claims are continuing to move forward in the U.S. District Court, Western District of Louisiana, where a federal Actos bladder cancer lawsuit litigation is currently underway. In April 2014, the first trial in this proceeding concluded with a $1.5 million compensatory damage award to the Plaintiff, whose case argued that Takeda had concealed bladder cancer risks associated with its Type 2 diabetes drug. Jurors in the lawsuit also ordered the manufacturer, as well as Eli Lilly & Co., who served as co-defendant, to pay a total of $9 billion in punitive damages after they were found to have “acted with wanton and reckless disregard.” According to the verdict reached on April 7, 2014, Takeda is ordered to pay $6 billion of the punitive damage award, and Eli Lilly has been assessed the remaining $3 billion.
Court records in March 2014 show nearly 3,000 Actos lawsuit filings now pending in the Western District of Louisiana.
How to File an Actos Lawsuit
For more information about filing a diabetes drug claim against Takeda, call an Actos attorney at Bernstein Liebhard LLP today. The Firm can be reached directly at .